The effect of aspirin in the recurrence of colorectal adenomas: A meta-analysis of randomized controlled trials

Colorectal Disease

Volumn 11, Issue 9, 2009, Pages 893-901

  Gao, F ^a   Liao, C ^a   Liu, L ^a   Tan, A ^a   Cao, Y ^a   Mo, Z ^b  

^a Department of Colorectal and Anal Surgery ^*  (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Asprin; Colorectal adenoma; Meta analysis; Recurrence

Indexed keywords

ACETYLSALICYLIC ACID; FOLIC ACID; PLACEBO;

CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG MEGADOSE; FOLLOW UP; HUMAN; INCIDENCE; LOW DRUG DOSE; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION;

ADENOMA; ASPIRIN; COLORECTAL NEOPLASMS; CYCLOOXYGENASE INHIBITORS; HUMANS; NEOPLASM RECURRENCE, LOCAL;

EID: 72949123788     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/j.1463-1318.2008.01746.x     Document Type: Review

References (53)

1. Peipins LA, Sandler R.S. Epidemiology of colorectal adeno-mas. Epidemiol Rev 1994; 16: 273-97.
2. Neugut AI, Jacobson JS, DeVivo I. Epidemiology of colorectal adenomatous polyps. Cancer Epidemiol Biomar-kers Prev 1993; 2: 159-76.
3. Cotton S, Sharp L, Little J. The adenoma-carcinoma sequence and prospects for the prevention of colorectal neoplasia. Crit Rev Oncog 1996; 7: 293-342.
4. Itzkowitz S.H. Gastrointestinal adenomatous polyps. Semin Gastrointest Dis 1996; 7: 105-16.
5. Ghadirian P, Maisonneuve P, Perret C et al. Epidemiology of sociodemographic characteristics, lifestyle, medical history, and colon cancer: a case-control study among French Cana-dians in Montreal. Cancer Detect Prev 1998; 22: 396-404.
6. Ferlay J, Bray F, Pisani P et al. (2004) GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase no. 5, version 2.0. IARC Press, Lyon.
7. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-67.
8. Bonithon-Kopp C, Piard F, Fenger C, Cabeza E, O'Morain C, Kronborg O, Faivre J; European Cancer Prevention Organization Study Group. Colorectal adenoma character-istics as predictors of recurrence. Dis Colon Rectum 2004; 47: 323-33.
9. Wegener M, Borsch G, Schmidt G. Colorectal adenomas. Distribution, incidence of malignant transformation, and rate of recurrence. Dis Colon Rectum 1986; 29: 383-7.
10. IARC Working Group on the Evaluation of Cancer Preventive Agents (1997) Non-Steroidal Anti-Inflammatory Drugs. Lyon, International Agency for Research on Cancer. World Health Organization, Lyon.
11. Kauppi M, Pukkala E, Isomaki H. Low incidence of colorectal cancer in patients with rheumatoid arthritis. Clin Exp Rheumatol 1996; 14: 551-3.
12. La Vecchia C, Negri E, Franceschi S, Conti E, Montella M, Giacosa A, Falcini A, Decarli A. Aspirin and colorectal cancer. Br J Cancer 1997; 76: 675-7.
13. Rosenberg L, Louik C, Shapiro S. Nonsteroidal antiinflam-matory drug use and reduced risk of large bowel carcinoma. Cancer 1998; 82: 2326-33.
14. Neugut AI, Rosenberg DJ, Ahsan H et al. Association between coronary heart disease and cancers of the breast, prostate, and colon. Cancer Epidemiol Biomarkers Prev 1998; 7: 869-73.
15. Bucher C, Jordan P, Nickeleit V, Torhorst J, Mihatsch M.J. Relative risk of malignant tumors in analgesic abusers. Effects of longterm intake of aspirin. Clin Nephrol 1999; 51: 67-72.
16. Smalley W, Ray WA, Daugherty J, Griffin M.R. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch Intern Med 1999; 159: 161-6.
17. Collet JP, Sharpe C, Belzile E, Boivin JF, Hanley J, Abenhaim L. Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: effects of dosage and timing. Br J Cancer 1999; 81: 62-8.
18. Langman MJ, Cheng KK, Gilman EA, Lancashire R.J. Effect of anti-inflammatory drugs on overall risk of common cancer: casecontrol study in general practice research data-base. BMJ 2000; 320: 1642-6.
19. Coogan PF, Rosenberg L, Louik C, Zauber AG, Stolley PD, Strom BL, Shapiro S. NSAIDs and risk of colorectal cancer according to presence or absence of family history of the disease. Cancer Causes Control 2000; 11: 249-55.
20. Kune GA, Kune S, Watson L.F. Colorectal cancer risk, chronic illness, operations and medications: case-control results from the Melbourne Colorectal Cancer Study. Cancer Res 1998; 48: 4399-404.
21. Giovanucci E, Rimm EB, Stamfer MJ, Colditz GA, Ascherio A, Willett W.C. Aspirin use and the risk for colorectal cancer adenoma in male health professionals. Ann Intern Med 1994; 121: 241-6.
22. Giovanucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willet WC, Speizer F.E. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995; 333: 609-14.
23. Muller AD, Sonnenberg A, Wasseman I.H. Diseases preced-ing colon cancer: a case control study among veterans. Dig Dis Sci 1994; 39: 2480-4.
24. Peleg II, Maibach HT, Brown SH, Wilcox C.M. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 1994; 154: 394-9.
25. Hixson LJ, Earnest DL, Fennerty MB, Sampliner R.E. NSAID effect on sporadic colon polyps. Am J Gastroenterol 1993; 88: 1652-6.
26. Wishingrad M, Titzer D, Triadafopoulos G, Omary B. Chronic aspirin and NSAID use may protect against colorectal adenomas (abstr). Gastroenterology 1994; 112: A452.
27. Macrae FA, Russell A, MacLennan R. Aspirin effects on large adenomas (abstr). Gastroenterology 1994; 112: A413.
28. Tosteson T, Greenberg E, Baron J. Aspirin use and reduced occurrence of large bowel adenomas (abstr). Gastroenterol-ogy 1995; 108: A39.
29. Johanson JF, Salisbury D. Effectiveness of aspirin in preventing colorectal adenomas: does dose matter (abstr)? Gastroenterology 1995; 114: A606.
30. Kahn HS, Tatham LM, Thun MJ, Heath C.W. Risk factors for self-reported colon polyps. J Gen Intern Med 1998; 13: 303-10.
31. Sandler RS, Galanko JC, Murray SC, Helm JF, Woosley J.T. Aspirin and nonsteroidal anti-inflammatory agents and risk for colorectal adenomas. Gastroenterology 1998; 114: 441- 7.
32. Garcia Rodriguez LA, Huerta-Alvarez C. Reduced inci-dence of colorectal adenoma among long-term users of nonsteroidal antiinflammatory drugs: a pooled analysis of published studies and a new population-based study. Epidemiology 2000; 11: 376-81.
33. Breuer-Katschinski B, Nemes K, Rump B, Leiendecker B, Marr A, Breuer N, Goebell H. Long-term use of nonste-roidal antiinflammatory drugs and the risk of colorectal adenomas. The Colorectal Adenoma Study Group. Diges-tion 2000; 61: 129-34.
34. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup D.F. Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 1999; 354: 1896-900.
35. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay H.J. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
36. Kjaergard LL, Villumsen J, Gluud C. Reported methodo-logic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2001; 135: 982-9.
37. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen T.P. Does quality of reports of random-ized trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998; 352: 609-13.
38. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. (2000) Methods for Meta-Analysis in Medical Research. Wiley, Chichester.
39. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335-71.
40. Egger M, Smith GD, Altman D.G. (2001 2nd edition) Systematic Reviews in Health Care: Meta-Analysis in Con-text. BMJ Books, London.
41. Sandler RS, Halabi S, Baron JA et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003; 348: 883- 90.
42. Baron JA, Cole BF, Sandler RS et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348: 891-9.
43. Benamouzig R, Deyra J, Martin A et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 2003; 125: 328-36.
44. Logan RF, Grainge MJ, Shepherd VC et al. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 2008; 134: 29-38.
45. Flossmann E, Rothwell P.M. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from rando-mised and observational studies. Lancet 2007; 369: 1603- 13.
46. Chan AT, Giovannucci EL, Meyerhardt JA et al. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 2005; 294: 914-23.
47. Kabashima K, Saji T, Murata T et al. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest 2002; 109: 883-93.
48. Krause W, DuBois R.N. Eicosanoids and the large intestine. Prostaglandins Other Lipid Mediat 2000; 61: 145-61.
49. Shureiqi I, Lippman S.M. Lipoxygenase modulation to reverse carcinogenesis. Cancer Res 2001; 61: 6307-12.
50. Gann PH, Manson JE, Glynn RJ et al. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 1993; 85: 1220-4.
51. Cook NR, Lee IM, Gaziano JM et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005; 294: 47-55.
52. Dube CD, Rostom A, Lewin G et al. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. preventive services task force. Ann Intern Med 2007; 146: 365-75.
53. Asano TK, McLeod R.S. Nonsteroidal anti-inflammatory drugs and aspirin for the prevention of colorectal adenomas and cancer: a systematic review. Dis Colon Rectum 2004; 47: 665-73.